 |
|
|
| |
Risk of Multiple Drug Interactions Potentially Linked to Safety in Patients
Receiving Pangenotypic Direct-acting Antivirals for the Treatment of Hepatitis C
|
| |
| |
AASLD 2021 Nov 12-16
Juan Turnes1, Antonio García-Herola2, Ramón Morillo3, Marinela Méndez4, Magdalena Rueda4, Cándido Hernández5, Antoni Sicras-Mainar6
1Gastroenterology and Hepatology Department, CHU. Pontevedra, Spain; 2Digestive Medicine Department. Hospital Marina Baixa de Villajoyosa (Alicante), Spain; 3Hospital Pharmacy, Hospital de Valme, AGS Sur de Sevilla, Spain; 4Medical Affairs, Gilead Sciences S.L., Madrid, Spain; 5Global Medical Affairs, Gilead Sciences Europe Ltd, U.K; 6Health Economics and Outcomes Research, Atrys Health, Barcelona, Spain
|
| |
|
|
|
|
|
